Latest News

Tuesday, December 18, 2018

New Drug Application Submitted for Therapy for Multiple Sclerosis

A New Drug Application (NDA) has been submitted to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for treating relapsing forms of mult…

Read the full story

Monday, December 17, 2018

Sleep Apnea Can Double Risk of Hard-to-Treat Hypertension in African-Americans

A new study published in Circulation reveals that African-Americans with moderate or severe sleep apnea are twice as likely to have hard-to-control high blood pressure when their sleep apnea…

Read the full story

Thursday, December 13, 2018

Long-Term Safety and Tolerability of Rimegepant for Treatment of Migraine

Initial results from an ongoing, open-label safety study of the oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, show that the drug may be effective and safe for acute trea…

Read the full story

Wednesday, December 12, 2018

Increased Dementia Risk for Female Veterans Who Experienced Brain Injuries

In a study published in Neurology, it was found that women who served in the military and have traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), or depression are more likely ev…

Read the full story

Tuesday, December 11, 2018

Large Global Registry of Stroke-Inducing Blood Clots Launched

The single largest global registry will collect and analyze stroke-inducing blood clots removed from the brain by thrombectomy. The Excellent Registry will enroll up to 1,000 ischemic stroke patients …

Read the full story

Monday, December 10, 2018

Tau Aggregation Inhibitor Receives Orphan Drug Status for Treatment of Frontotemporal Dementia

Orphan drug designation has been granted to a tau aggregation inhibitor leucomethylthioninium (LMTX) (TauRx, Aberdeen, Scotland) being studied in phase 3 clinical trials for the treatment of frontotem…

Read the full story

Monday, December 10, 2018

New Drug Candidate for Alzheimer’s Disease to Enter Phase 1 Trials

The investigational drug candidate E2814, designed to slow the progression of Alzheimer’s disease, will enter phase 1 clinical trials in early 2019. A monoclonal antibody, E2814 targets tau &…

Read the full story

Friday, December 07, 2018

Fenfluramine Reduces Seizure Frequency in Patients With Dravet Syndrome

Results of a second phase 3 trial (Study 1504) and an ongoing open-label extension study (Study 1503) of fenfluramine for treatment of patients with Dravet syndrome showed that patients who took low-d…

Read the full story

Friday, December 07, 2018

Lower Starting Dose of Cenobamate Alleviates Side Effect of DRESS Syndrome

At the American Epilepsy Society annual meeting in New Orleans, LA, results were presented from a large phase 3 safety study of the investigational antiepileptic drug, cenobamate (YKP3089; SK Life Sci…

Read the full story

Wednesday, December 05, 2018

Perampanel Has Long-Term Convulsive Seizure Freedom, Efficacy at Lower Dose, and Was Recently Approved for Children Age 4 to 12 Years

Recently approved for use in children, age 4 and up, monotherapy or adjunctive treatment with perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) is approved for treatment of partial onset seizures (POS) …

Read the full story

Wednesday, December 05, 2018

FDA Accepts Application for Genetic Treatment of Spinal Muscular Atrophy Type 1

The Food and Drug Administration (FDA) has accepted the Biologics License Application for onasemnogene abeparvovec-xxxx (AVXS-101, Zolgensma; AveXis, Bannockburn, Illinois), an investigational ge…

Read the full story

Wednesday, December 05, 2018

Positive Results in Phase 3 Trial of Rimegepant for Oral Acute Treatment of Migraine

Results from a phase 3 clinical trial show that treatment with rimegepant (Zydis; Biohaven, New Haven, CT) provided significantly more relief from pain and most bothersome symptoms (MBS) compared with…

Read the full story

Wednesday, December 05, 2018

Brivaracetam Efficacy for Treating Acute Seizures in Epilepsy Monitoring Unit

At the American Epilepsy Society Annual Meeting in New Orleans, LA, data were presented from an open-label, randomized, parallel-group, active control study (NCT03021018) and showed brivaracetam (BRV)…

Read the full story

Tuesday, December 04, 2018

Midazolam Nasal Spray Safety and Efficacy Results Reported

In results presented at the American Epilepsy Society’s annual meeting in New Orleans, LA, midazolam nasal spray (USL261; UCB, Atlanta, GA), a drug being investigated for treatment of acute repe…

Read the full story

Tuesday, December 04, 2018

Dystonia and Spasticity Patients May Become Immune to Toxin Treatment

People with dystonia or spasticity can get relief from botulinum toxin type A, but a new study published online in Neurology shows that 15% of people treated with the toxin can develop an im…

Read the full story
Load More